Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 130.18% | 285.10% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.79% | -11.61% | -- | -- | -- |
| Operating Income | 10.79% | 11.61% | -- | -- | -- |
| Income Before Tax | 37.20% | -9.59% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.20% | -9.59% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.20% | -9.59% | -- | -- | -- |
| EBIT | 10.79% | 11.61% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 91.67% | 43.65% | -- | -- | -- |
| Normalized Basic EPS | 91.67% | 43.65% | -- | -- | -- |
| EPS Diluted | 91.67% | 43.65% | -- | -- | -- |
| Normalized Diluted EPS | 91.67% | 43.65% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,039.90% | 310.04% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,039.90% | 310.04% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |